

Curriculum Vitae

Richard H. Grimm, Jr., M.D., Ph.D.

Berman Center for Outcomes and Clinical Research
825 S. Eighth St., Ste 440
Minneapolis, MN 55404
Minneapolis Medical Research Foundation
Division of Clinical Epidemiology, Department of Medicine
Hennepin County Medical Center
701 Park Avenue South
Minneapolis, MN 55415
Phone: (612) 347-7755 Fax: (612) 347-7761

Date of Birth: August 22, 1946
Place of Birth: Oklahoma City, OK
Medical License: Minnesota 22362

Education

- | | | |
|--------------|---|--------------------------------|
| 1984: | University of Minnesota
Laboratory of Physiological Hygiene
School of Public Health
Minneapolis, MN | Ph.D. |
| 1978: | University of Minnesota
Laboratory of Physiological Hygiene
Minneapolis, MN | M.P.H. |
| 1975 - 1985: | Research Fellow
Division of Epidemiology (incorporating the Laboratory of Physiological Hygiene)
University of Minnesota
Minneapolis, MN | |
| 1973 - 1975: | Cornell Cooperating Hospitals
Memorial Hospital, Department of Internal Medicine
North Shore University Hospital
New York City and Manhasset, NY | Internal Medicine
Residency |

1973 - 1974:	Duke University Medical Center Robert Wood Johnson Clinical Scholar	
1972 - 1973:	Metropolitan Hospital New York Medical College Internal Medicine New York, NY	Medicine Internship
1972:	University of Oklahoma College of Medicine Oklahoma City, OK	M.D.
1968:	University of Oklahoma Norman, Oklahoma	B.A.

Honors

1984:	American Heart Association	Established Investigator
1975:	American Heart Association Council on Cardiovascular Epidemiology First U.S. Seminar Lake Tahoe, California	Fellow
1973 - 1974:	Duke University Medical Center	Robert Wood Johnson Clinical Scholar
1999:	American Society of Hypertension	Clinical Hypertension Specialist

Areas of Research

Hypertension, Preventive Cardiology, Epidemiology
Complimentary and Alternative Medicine

Appointments

1996 - date	Director Berman Center for Outcomes and Clinical Research Minneapolis Medical Research Foundation Minneapolis, MN
	Chief Division of Clinical Epidemiology

Hennepin County Medical Center
Minneapolis, MN

Professor
Cardiovascular Division, Internal Medicine
Medical School, University of Minnesota
Minneapolis, MN

Professor
Division of Epidemiology
School of Public Health, University of Minnesota
Minneapolis, MN

1994 to date: Professor
Cardiovascular Division, Internal Medicine
Medical School, University of Minnesota
Minneapolis, MN

Associate Professor
Division of Epidemiology
School of Public Health, University of Minnesota
Minneapolis, MN
Medical Director
Berman Center for Clinical Research
Minneapolis, MN

1992 - 1994: Associate Professor
Cardiovascular Division, Internal Medicine
Medical School, University of Minnesota
Minneapolis, MN

Associate Professor
Division of Epidemiology
School of Public Health, University of Minnesota
Minneapolis, MN

Medical Director
Berman Center for Clinical Research
Minneapolis, MN

1991 to date: Medical Director
Berman Center for Clinical Research
Minneapolis, MN

Associate Professor
Division of Epidemiology
School of Public Health, University of Minnesota
Minneapolis, MN

1988 - 1991: Associate Professor
Division of Epidemiology
School of Public Health, University of Minnesota
Minneapolis, MN

1985 - 1988: Assistant Professor
Division of Epidemiology
School of Public Health, University of Minnesota
Minneapolis, MN

1975 - 1985: Research Fellow
Division of Epidemiology (incorporating the Laboratory of Physiological
Hygiene)
University of Minnesota
Minneapolis, MN

Committee Memberships

American Heart Association

1986 - 1987: President, Minnesota Affiliate
1990: Member of AHA Hypertension Prevention Conference II
1989: Invited Participant in National Medical Writers Symposium
1989 - date: Basic Science Council Member, Council on Epidemiology Member
1986 - 1988: Executive Committee Member--Epidemiology Council
1997 - date Fellow, High Blood Pressure Council
1997 - date Member, Basic Science Council
1997 - date Fellow, Council on Epidemiology and Prevention

NIH

2002: Ancillary Studies in Heart, Lung, and Blood Disease Trials Review Panel
2000: Chair of Data and Safety Monitoring Board for trials in the National Center
for Complimentary and Alternative Medicine
1998 - 2002: National Center for Complimentary and Alternative Medicine (NCCAM)
Scientific Advisory Council
1997: Reviewer for the Joint National Committee on Detection, Evaluation, and
Treatment of High Blood Pressure (JNC VI)

- 1996: Chair of Data and Safety Monitoring Board for NHLBI, DASH II Study
- 1994: Regional Coordinator - ALLHAT Study (NHLBI)
- 1993: NHLBI Working Group on Primary Prevention of Hypertension; Member.
- 1993: The Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V) Drug Selection Sub-committee; Member.
- 1993: ALLHAT Planning Committee--NHLBI
- 1992 - 1993: Data and Safety Monitoring Board for the Cancer Prevention Research Unit (CPRU); Member.
- 1992 - 1993: National High Blood Pressure Education Program; Member.
- 1989 - date: Dietary Intervention Study in Children (DISC) Data and Safety Monitoring Board--NHLBI
- 1980-Present: NHLBI Ad Hoc Reviewer
- 1997-Present Dietary Approches to Stopping Hypertension II (DASH II) Data and Safety Monitoring Board--NIH

Board Memberships

- 1990 - date: PACER (Parents Advocacy Coalition for Children with Disabilities)
- 1980 - 1989: Minnesota Affiliate American Heart Association
- 1996 - 1998: Minneapolis Medical Research Foundation Board of Directors
- 2000 - date: Center for Addiction and Alternative Medicine Research Advisory Board

Editorial Boards

- 1997: *Cardiovascular Therapeutics*
- 1998 - date: *Hypertension*
- 1999 - date: *Heart Disease*
- 1999 - date: *American Journal of Hypertension*

Consultantships

- 1991: Southern African Hypertension Society

Other Committees and Positions

Study Positions:

- Multiple Risk Factor Intervention Trial (MRFIT): Clinical Center, Minneapolis, Minnesota; Principal Investigator; Steering Committee Member; Vice Chairman and Hypertension Representative of Intervention Committee.
- Control of Hypertension by Non-Pharmacologic Means--The Hypertension Control Program (HCP); Principal Investigator; Steering Committee Member.

Hypertension Prevention Trial (HPT); Co-Principal Investigator; Steering Committee Member.

Potassium and Sodium to Control Blood Pressure in Hypertensives: The Mount Sinai Hypertension Trial (MSHT); Principal Investigator.

Systolic Hypertension in the Elderly Program (SHEP): Minneapolis Center Principal Investigator; Steering Committee Member; Publications and Presentations Committee Member.

The Treatment of Mild Hypertension Study (TOMHS); Principal Investigator; Chair - Publications and Presentations Committee.

Study of Osteoporotic Fractures (SOF); Co-Principal Investigator, 1992 - 1993; Principal Investigator, 1986 - 1992.

Fracture Intervention Trial (FIT); Principal Investigator; Steering Committee Member.

Sodium Sensitivity in Blacks Study (SNaP); Principal Investigator; Chair - Executive Committee; Chair - Publications and Presentations Committee.

Women's Health Initiative (WHI), Vanguard Clinical Center, Minneapolis, Minnesota; Principal Investigator; Investigator's Committee Member; Morbidity and Mortality Committee Member.

Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Principal Investigator - Region 7, Chair - Publications and Ancillary Studies Subcommittee; Steering Committee Member; Editorial and Dissemination Committee Member.

Treatment of Hypertension with Alternative Therapies (THAT) Study, Principal Investigator.

Controlled Onset Verapamil Investigation for Cardiovascular Endpoints (CONVINCE) Trial, Chair - Publications and Ancillary Studies Committee; Executive Committee Member.

Dietary Interventions Study in Children (DISC), Data Safety and Monitoring Board Member

Dietary Approaches to Stop Hypertension II (DASH II), Chair-Data Safety and Monitoring Board

Omni-Heart Study, Chair-Data Safety and Monitoring Board

Action to Control Cardiovascular Risk in Diabetes (ACCORD), Principal Investigator – Minnesota Iowa Clinical Center Network, Chair – Medical Interventions Committee.

United States Renal Data System (USRDS), Co-Investigator

National Kidney Foundation - Kidney Disease Outcomes Quality Initiative (NKF-DOQI), Advisory Board

Kidney Disease Outcomes Quality Initiative (KDQI), Lipid Treatment Guidelines Panel Member

National Kidney Foundation - Kidney Early Evaluation Program 3.0 (NKF – KEEP 3.0), Steering Committee Member

Losartan Intervention for Endpoint Reduction in Hypertension (LIFE), Investigator

Trial of Preventing Hypertension (TROPHY), Steering Committee Member

Blue Cross Blue Shield of Minnesota, Provider Advisory Council

National Kidney Foundation, Member of Advisory Board

Reviewer Positions

Circulation, Hypertension, Archives of Internal Medicine, Annals of Internal Medicine, American Journal of Cardiology, American Journal of Hypertension, Cochrane Review Group for Hypertension, Diabetes, Journal of the American Geriatric Association, Preventive Medicine, Metabolism, Journal American Medical Association, American Journal of Public Health, American Heart Journal, Journal of Clinical Trials.

Abstract Reviewer Positions

American College of Epidemiology, American Society of Hypertension, American Heart Association Council on Epidemiology, International Society of Hypertension, Preventive Medicine, Hypertension, Circulation.

Professional Societies

Association of Black Cardiologists; Member.
American Heart Association Council on Epidemiology and Prevention; Fellow.
American Heart Association Basic Science Council; Member.
American Society of Hypertension; Program Committee Faculty; Public Policy Committee Member; Member.
Council for High Blood Pressure Research; 1996 Fellow.
International Society of Hypertension; Member.
International Society of Hypertension in Blacks; Member.

Publications

1. **RH Grimm**, K Shimoni, WR Harlan, EH Estes. Evaluation of patient care protocol by various providers. *N Engl J Med* 1975;292:507.
2. WR Harlan, A Oberman, **R Grimm**, R Rosati. Chronic congestive heart failure in coronary artery disease: Clinical criteria. *Ann Intern Med* 1977;86:133-138.
3. RD Thorsen, D Jacobs, **RH Grimm**, A Keys, H Taylor, H Blackburn. Preventive cardiology in practice: A device for risk estimation and counseling in coronary disease. *Prev Med* 1979;8:548-556.

4. **RH Grimm**, AS Leon, DB Hunninghake, K Lenz, P Hannan, H Blackburn. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: A double-blind controlled trial. *Ann Intern Med* 1981;94:7-11.
5. **RH Grimm**, AS Leon, D Hunninghake, H Blackburn. Diuretics and plasma lipids: Effects of thiazides and spironolactone. In: G Nosedá, C Fragiaco, R Fumagealli, R Paoletti, (Eds.): Lipoproteins and coronary atherosclerosis; proceedings of the International Symposium on Lipoproteins and Coronary Atherosclerosis; Lugano, Switzerland; October 1-3, 1981. Elsevier Biomedical Press 1982;371-376.
6. J Cohen, D Jerome, **RH Grimm**, W McFate-Smith. Multiple Risk Factor Intervention Trial (MRFIT); VI. Intervention and blood pressure. *Prev Med* 1981;10(4):501-518.
7. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial (MRFIT): Risk factor changes and mortality results. *JAMA* 1982;248:1465-1477.
8. **RH Grimm**, RV Luepker, H Taylor, H Blackburn. Long-term effects of a blood pressure survey on patient treatment in a community. *Circulation* 1982;65:946-950.
9. **RH Grimm**, for the Multiple Risk Factor Intervention Trial Research Group. The Multiple Risk Factor Intervention Trial: A summary of results at four years in special intervention and usual care men. *Prev Med* 1983;12:185-190.
10. TF Pechacek, **RH Grimm**. Cigarette smoking and the prevention of coronary disease: Principles for effective smoking cessation programs for health professionals. In: RN Podell, MM Steward (Eds.): Primary prevention of coronary heart disease: A practical guide for the clinician, Palo Alto, Addison-Wesley 1983;34-77.
11. R Skekelle, A Caggiula, **RH Grimm**. Diuretic treatment of hypertension and changes in plasma lipids over six years in the Multiple Risk Factor Intervention Trial. In: RJ Hegyeli, (Ed.): Atherosclerosis Reviews, New York, Raven Press 1984;12:113-127.
12. AS Leon, J Agre, **RH Grimm**, et al. Blood lipid effects of antihypertensive therapy: A double-blind comparison of the effects of methyldopa and propranolol. *J Clin Pharm* 1984;24:209-217.
13. **RH Grimm**. Should mild hypertension be treated? Early intervention. *Med Clin North Am* 1984;68:477-490.

14. RV Luepker, **RH Grimm**, HL Taylor. The effects of “usual care” on cardiovascular risk factors in a clinical trial. *Cont Clin Trials* 1984;5:47-53.
15. R Stamler, J Stamler, **R Grimm**, F Gosch, A Dyer, R Berman, J Civinelli, P Elmer, J Fishman, N Van Heel, et al. Trial on control of hypertension by nutritional means: Three-year results. *J of Hyp Suppl* 1984;2(3):S167-70.
16. NL Lasser, G Grandits, AW Caggiula, JA Cutler, **RH Grimm**, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. *Am J Med* 1984;76:52-66.
17. **RH Grimm**, JD Neaton, M McDonald, J Case, D Kousch, J Childs, et al., for the Multiple Risk Factor Intervention Trial Research Group. Beneficial effects from systematic dosage reduction of the diuretic, chlorthalidone: A randomized study within a clinical trial. *Am Heart J* 1985;109(4):858-864.
18. **RH Grimm**, J Cohen, WM Smith, L Falvo-Gerard. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT): Six-year intervention and usual care groups. *Arch Intern Med* 1985;145:1191-1199.
19. **RH Grimm**, JD Neaton, W Ludwig. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. Results from the Multiple Risk Factor Intervention Trial. *JAMA* 1985;254(14):1932-1937.
20. GS Tell, **RH Grimm**, OD Vellar, L Theodorsen. The relationship of white blood cell count, platelet count and hematocrit to cigarette smoking in adolescents: The Oslo Youth Study. *Circulation* 1985;72(5):971-974.
21. AR Folsom, JR Hughes, JF Buehler, MB Mittelmark, DR Jacobs, **RH Grimm**, for the Multiple Risk Factor Intervention Trial Group. Do Type A men drink more frequently than Type B men? Findings in the Multiple Risk Factor Intervention Trial (MRFIT). *J Behav Med* 1985;8(3):227-235.
22. H Blackburn, **RH Grimm**, RV Luepker, M Mittelmark. The primary prevention of high blood pressure: A population approach. *Prev Med* 1985;14:466-481.
23. R Stamler, J Stamler, **RH Grimm**, A Dyer, FC Gosch, R Berman, P Elmer, J Fishman, N Van Heel, J Civinelli, R Hoeksema. Nonpharmacological control of hypertension. *Prev Med* 1985;14:336-345.
24. M McDonald, **RH Grimm**. Compliance with hypertension treatment. *Postgrad Med* 1985;77(8):233-242.

25. **RH Grimm**, PJ Elmer, JD Neaton, MS Segal, RJ Prineas. Role of potassium supplementation and sodium reduction in controlling blood pressure in hypertensive men: Design and methods of the Mount Sinai Hypertension Trial (MSHT). In: Whelton, Whelton, Walker (Eds.): Potassium in Cardiovascular and Renal Medicine, New York, Marcel Dekker, Inc. 1985;401-410.
26. **RH Grimm**, W McFate-Smith, SB Hulley. The Hypertension Intervention Program. In: U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, Maryland, Multiple Risk Factor Intervention Trial (MRFIT) Monograph, Materials and methods for a cardiovascular disease risk factor reduction program: A resource from the Multiple Risk Factor Intervention Trial, Springfield, Virginia, National Technical Information Center (NTIC), NIH Publication 1985;85-1267, Chapter 5:202-332.
27. DM Murray, RV Luepker, **RH Grimm**, H Blackburn. Prevention and treatment of hypertension at a community level: The Minnesota Heart Health Program. In: MJ Horan, IK Shkvatsabaya (Eds.): Proceedings from the fourth US-USSR joint symposium on arterial hypertension, *Kardiologia* 1986;26:78-84-6.
28. **RH Grimm**. The drug treatment of mild hypertension: A review. *Drugs* 1986;31(Suppl 1):13-21.
29. AR Folsom, CL Smith, RJ Prineas, **RH Grimm**. Serum calcium fractions in essential hypertensive and matched normotensive subjects. *Hypertension* 1986;8(1):11-15.
30. AR Leon, C McNally, D Casal, **R Grimm**, R Crow, C Bell, DB Hunninghake. Enalapril alone and in combination with hydrochlorothiazide in the treatment of hypertension: Effect on treadmill exercise performance. *J Cardiopulmonary Rehab* 1986;6:251-256.
31. MB Mittelmark, RV Luepker, D Jacobs, NF Bracht, R Carlaw, R Crow, J Finnegan, **RH Grimm**, et al. Community-wide prevention of cardiovascular disease: Education strategies of the Minnesota Heart Health Program. *Prev Med* 1986;15:1-17.
32. **RH Grimm**, et al, for the MRFIT Research Group. Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Intervention Trial (MRFIT). *Am J Cardio* 1986;58:1-13.
33. MB Mittelmark, RV Luepker, D Jacobs, NF Bracht, R Carlaw, R Crow, J Finnegan, **RH Grimm**, et al. Community-wide prevention of cardiovascular disease: Education strategies of the Minnesota Heart Health Program. *Prev Med* 1986; 15:1-17.

34. **RH Grimm**, DB Hunninghake. Lipids and hypertension: Implications of new guidelines for cholesterol management in the treatment of hypertension. *Am J Med* 1986;80(2A):56-63.
35. **RH Grimm**, RJ Prineas. The effects of sodium reduction on control of blood pressure elevation: A review. Non-pharmacologic therapy of hypertension. *Bibliotheca Cardiologica Series*, Karger Press, 1986.
36. R Stamler, J Stamler, **RH Grimm**, F Gosch, R Berman N Van Heel, P Elmer, J Civinelli. Non-pharmacologic control of blood pressure in hypertensives previously treated with drugs. Book chapter—Schattauer Publishers 1987.
37. AR Dyer, R Stamler, **R Grimm**, J Stamler, R Berman, FC Gosch, LA Emidy, P Elmer, J Fishman, N Van Heel, G Civinelli. Do hypertensive patients have a different diurnal pattern of electrolyte excretion? *Hypertension* 1987;10:417-424.
38. R Stamler, J Stamler, **RH Grimm**, F Gosch, P Elmer, A Dyer, R Berman, J Fishman, N Van Heel, J Civinelli, A McDonald. Nutritional therapy for high blood pressure: Final report of a 4-year randomized controlled trial — The Hypertension Control Program. *JAMA* 1987;257(11): 1484-1491.
39. **RH Grimm**, S Tillinghast, K Daniels, JD Neaton, S Mascioli, R Crow, M Pritzker, RJ Prineas. Unrecognized myocardial infarction: Experience in the Multiple Risk Factor Intervention Trial (MRFIT). Presented at the NIH Workshop on Silent Coronary Artery Disease. *Circulation* 1987;75(Suppl II):60-8.
40. AR Folsom, **RH Grimm**. Stop smoking advice by physicians: A feasible approach? *Am J Pub Health* 1987;77:849-850.
41. **RH Grimm**. Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT). *Cont Clin Trials* 1987;8(4):41S-53S.
42. J Stamler, RJ Prineas, JD Neaton, **RH Grimm**, RH McDonald, HW Schnaper, JA Schoenberger, PJ Elmer, JA Cutler. Background and design of the new U.S. trial on diet and drug treatment of “mild” hypertension (TOMHS). *Am J Cardio* 1987;59:51G-60G.
43. **RH Grimm**. Thiazide diuretics and selective alpha blockers: Comparison of use in antihypertensive therapy, including possible differences in coronary heart disease risk reduction. *Am J of Med* 1987;82(Suppl 1A):43-57.

44. **RH Grimm.** Lipid effects of antihypertensive agents: An overview. *Choices in Cardio* 1988;2(5):208-210.
45. MB Mittelmark, RV Luepker, **RH Grimm**, TE Kottke, H Blackburn. The role of physicians in a community-wide program for prevention of cardiovascular disease: The Minnesota Heart Health Program. *Public Health Reports* 1988;103(4):360-365.
46. **RH Grimm**, PM Kofron, JD Neaton, KH Svendsen, PJ Elmer, L Holland, L Witte, D Clearman, R Prineas. Effect of potassium supplementation combined with dietary sodium reduction on blood pressure in men taking antihypertensive medication. *Hypertension* 1988;6(Suppl 4):S591-S593.
47. **RH Grimm**, for the Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rational and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. *J Clin Pharm* 1988; 41(12):1197-1208.
48. AM McDonald, AR Dyer, K Liu, R Stamler, FC Gosch, **R Grimm**, R Berman, J Stamler. Sodium, lithium-countertransport and blood pressure control by nutritional intervention in "mild" hypertension. *J Hypertension* 1988;6(4)283-91.
49. R Stamler, **RH Grimm**, AR Dyer, JV Talano, R Prineas, R Crow, R Berman, FC Gosch, P Elmer, J Stamler. Cardiac status after four years in a trial on nutritional therapy for high blood pressure. *Arch Intern Med* 1989;149:661-665.
50. **RH Grimm**, J Flack. The management of hypertension: Potential trade-offs on coronary risk. *Am J Med* 1989;87(2A):62S-65S.
51. **RH Grimm.** Alpha₁ inhibitors in the treatment of hypertension. *Hypertension* 1989;13(5):I131-I136.
52. JM Flack, **RH Grimm.** Diuretics. In: N Kaplan (Ed.): *Perspectives in Hypertension* 1989;17-32.
53. **RH Grimm**, et al. The cost effectiveness of antihypertensive therapy: The potential impact of secondary lipid changes. *Med Interface* 1989;2(5):27-38.
54. JM Flack, **RH Grimm.** Treating hypertension and lipids: A rational approach. *Med Management Dynamics* 1989;6:3-8.
55. **RH Grimm.** Treating hypertension and cardiovascular risk: Are there tradeoffs? *Am Heart J* 1990;119(3)Part 2:729-732.

56. **RH Grimm**, JM Flack, R Byington, G Bond, S Brugger, for the MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis--the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). *Drugs* 40 (Suppl 2) 1990;38-43.
57. **RH Grimm**, JD Neaton, PJ Elmer, KH Svendsen, J Levin, M Segal, L Holland, LJ Witte, DR Clearman, P Kofron, RK LaBounty, R Crow, RJ Prineas. The influence of potassium on blood pressure in hypertensive men on a low sodium diet: Results of a double-blind randomized trial. *New Eng J Med* 1990;322(9):569-574.
58. **RH Grimm**, et al., for the Multiple Risk Factor Intervention Trial. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: Findings related to apriori hypotheses of the trial. *JAMA* 1990;263:1795-1801.
59. GD Friedman, I Tekawa, **RH Grimm**, T Manolio, SG Shannon, S Sidney. The leucocyte count: Correlates and relationship to coronary risk factors; the CARDIA study. *International J of Epid* 1990;19(4):889-893.
60. LK Hansen, **RH Grimm**, JD Neaton. The relationship of white blood cell count to other cardiovascular risk factors. *International J of Epid* 1990;19:881-888.
61. SR Mascioli, **RH Grimm**, JD Neaton, J Stamler, RJ Prineas, R McDonald, H Schnaper, J Schoenberger, G Grandits, PJ Elmer, JA Cutler, for the TOMHS Research Group. The Treatment of Mild Hypertension Study (TOMHS): Characteristics of participants at baseline. *Am J Cardio* 1990;66(9):32C-35C.
62. JM Flack, K Ensrud, S Mascioli, **RH Grimm**, CA Launer, K Svendsen, PJ Elmer. Racial and ethnic modifiers of the salt-blood pressure response. *Hypertension* 1991;17(Suppl I):I115-I121.
63. J Wittes, B Davis, K Berge, J Cohen, **R Grimm**. Systolic Hypertension in the Elderly (SHEP) Part 10: Analysis. *Hypertension* 1991;17(Suppl II):II162-II167.
64. J Cutler, G Grandits, **R Grimm**, E Thomas, J Billings, N Wright, for the MRFIT Research Group. Risk factor changes after cessation of intervention in the Multiple Risk Factor Intervention Trial. *Prev Med* 1991;20:183-196.
65. **RH Grimm**. New multicenter trials in hypertension. *Current Opinion in Cardio* 1991;6:731-736.
66. S Mascioli, **RH Grimm**, CA Launer, K Svendsen, JM Flack, N Gonzalez, PJ Elmer, J Neaton. Sodium chloride raises blood pressure in normotensive subjects: The study of sodium and blood pressure. *Hypertension* 1991;17(Suppl I):I21-I26.

67. PJ Elmer, **RH Grimm**, JM Flack, B Laing. Dietary sodium reduction for hypertension prevention and treatment. *Hypertension* 1991;17(Suppl I):I182-I189.
68. The SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons: Final results of the Systolic Hypertension in the Elderly Program. *JAMA* 1991;265(24):3255-3264.
69. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study: A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. *Arch Int Med* 1991;151:1413-1423.
70. GE McVeigh, DE Burns, SM Finkelstein, KM McDonald, JE Mock, W Feske, PF Carlyle, JM Flack, **RH Grimm**, JN Cohn. Reduced vascular compliance as a marker for essential hypertension. *Am J Hypertension* 1991;4:245-251.
71. **RH Grimm**. Antihypertensive therapy: Taking lipids into consideration. *Am Heart J* 1991;122:910-8.
72. HR Black, SG Chrysant, CL Curry, WH Frishman, **RH Grimm**, KC Lasseter, R Okun, JL Pool, V Raizada, ND Vlachakis, et al. Antihypertensive and metabolic effects of concomitant administration of terazosin and methylothiazide for the treatment of essential hypertension. *J Clin Pharm* 1992;32(4):351-9.
73. AN Phillips, JD Neaton, DG Cook, **RH Grimm**, AG Shaper. The leukocyte count and risk of lung cancer. *Cancer* 1992;69:680-684.
74. KE Ensrud, MC Nevitt, C Yunis, SB Hulley, **RH Grimm**, SR Cummings. Postural hypotension and postural dizziness in elderly women: The study of osteoporotic fractures. *Arch Intern Med* 1992;152:1058-1064.
75. AN Phillips, JD Neaton, DG Cook, **RH Grimm**, AG Shaper. Leukocyte count and risk of major coronary heart disease events. *Am J of Epid* 1992;136(1):59-69.
76. AV Prochazka, TL Petty, L Nett, GW Silvers, DPL Sachs, SI Rennard, DM Daughton, **RH Grimm**, C Heim. Transdermal clonidine reduced withdrawal symptoms but did not increase smoking cessation. *Arch Intern Med* 1992;152:2065-2069.
77. JM Flack, A Woolley, P Esunge, **RH Grimm**. A rational approach to hypertension treatment in the older patient. *Geriatrics* 1992;47(11)24-37.

78. KA Pearce, **RH Grimm**, S Rao, K Svendsen, PR Liebson, JD Neaton, K Ensrud. Population-derived comparisons of ambulatory and office blood pressure: Implications for the determination of usual blood pressure and the concept of white coat hypertension. *Arch Intern Med* 1992;152:750-6.
79. JM Flack, P Esunge, **RH Grimm**. Isolated systolic hypertension: An approach to treatment. *Illustrated Med* 1992;7(1):2-15.
80. **R Grimm**. Antihypertensive treatment comparison trials: Quality of life effects. Chapter C21, Hypertension Primer. Ed. K Tauberg, JL Izzo, HR Black. American Heart Association, Dallas, TX 1993;202-204.
81. FA Lederle, WB Applegate, **RH Grimm**. Reserpine and the medical marketplace. *Arch Intern Med* 1993;191:705-706.
82. The National High Blood Pressure Education Program working group reports on primary prevention of hypertension. *Arch Int Med* 1993;153:186-208.
83. PR Liebson, GG Grandits, R Prineas, S Dianzumba, JM Flack, JA Cutler, **R Grimm**, J Stamler. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). *Circulation* 1993;87(2):476-486.
84. **RH Grimm**. Hypertension management in patients with diabetes. *Clin Diabetes* 1993;11(3):51.
85. **R Grimm**. Public health and community medicine. Chapter 6, Rypins' Medical Boards Review: Clinical Sciences. Ed. ED Frohlich. J.B. Lippincott Company; Lipcot, PA; 1993.
86. **RH Grimm**, LH Kuller, D Stoy. Chapter: Methodologic Issues--follow-up. Inclusion of elderly individuals in clinical trials: Cardiovascular disease and cardiovascular therapy as a model. NK Wenger (Ed.): 1993;94-96.
87. K Bradley, JM Flack, J Belcher, P Elmer, P Miller, **R Grimm**. Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. *Am J of Hypertension* 1993;6(7):636-639.
88. JD Neaton, **RH Grimm**, RJ Prineas, GA Grandits, PJ Elmer, JA Cutler, JM Flack, J Schoenberger, R McDonald, CE Lewis, PR Liebson, for the TOMHS Research Group. The Treatment of Mild Hypertension Study: Final results. *JAMA* 1993;270:713-724.

89. RJ Wilt, JW Sprinkle, JM Flack, C Heuer, N Borhani, A Merchant, HW Schnaper, W Applegate, **RH Grimm**. Prevalance and correlates of lower extremity arterial disease in hypertensive patients with carotid atherosclerosis: Baseline results from the Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS). *J of Vascular Med and Biology* 1993;4(2-3):95-101.
90. JM Flack, G McVeigh, **RH Grimm**. Hypertension in the elderly. *Current Science* 1993;2(3):386-394.
91. **RH Grimm**, P Elmer, RJ Prineas, G Grandits, K Svendsen. Insights on sodium from clinical trials (HCP, MSHT, TOMHS). Presented at the International Conference of the Academy of Nutritional Medicine, the German Kidney Foundation, the World Hypertension League and the Albert-Ludwigs-University; Freiburg, Germany; October 30, 1993.
92. D Strickland, JM Sprafka, RV Luepker, **RH Grimm**. Association of antihypertensive agents and blood lipids in a population-based survey. *Epidemiology* 1994;5(1):96-101.
93. JB Kostis, R Allen, DV Berkson, JD Curb, J Davey, **RH Grimm**, et al, for the SHEP Collaborative Research Group. Correlates of ventricular ectopic activity in isolated systolic hypertension. *Am Heart J* 1994;127(1):112-121.
94. JC LaRosa, W Applegate, JR Crouse, DB Hunninghake, **R Grimm**, R Knopp, JH Eckfeldt, CE Davis, DJ Gordan. Cholesterol lowering in the elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. *Arch Int Med* 1994;154:529-539.
95. J Kvasnicka, JM Flack, **RH Grimm**. Treatment of hypertension in the presence of coexisting medical conditions. *Drugs & Aging* 1994;4(4):304-312.
96. RV Luepker, DM Murray, DR Jacobs, MB Mittelmark, N Bracht, R Carlaw, R Crow, P Elmer, J Finnegan, AR Folsom, **R Grimm**, PJ Hannan, R Jeffrey, H Lando, P McGovern, R Mullis, CL Perry, T Pechacek, P Pirie, JM Sprafka, R Weisbrod, H Blackburn. Community education for cardiovascular disease prevention: Risk factor changes in the Minnesota Heart program. *Am J of Public Health* 1994;84(9);1383-93.
97. RJ Prineas, **R Grimm**, G Grandits, P Liebson, J Neaton, J Stamler, P Elmer, J Cutler, P Rautaharju. The effect of dietary sodium and body weight on echocardiographic measures of left ventricular mass among treated hypertensive men and women: four year change in TOMHS study. *Nieren- und Hochdruckkrankheiten* 1994;(Supp 1); S14-S21.

98. **RH Grimm, Jr.**, P Elmer, RJ Prineas, G Grandits, K Svendsen. Insights on sodium from clinical trials (HCP, MSHT, TOMHS). *Nieren- und Hochdruckkrankheiten* 1994;(Supp 1); S32-S37.
99. PA Abraham, SR Mascioli, CA Launer, JM Flack, PR Liebson, KH Svendsen, GA Grandits, JA Opsahl, JA Schoenberger, **RH Grimm**. Urinary albumin and n-acetyl-beta-d-glycosaminidase excretions in mild hypertension. *Am J of Hypertension* 1994;7:965-974.
100. GE McVeigh, J Flack, **R Grimm**. Goals of antihypertensive therapy. *Drugs* 1995;49(2):161-175
101. PR Liebson, GA Grandits, S Dianzumba, RJ Prineas, **RH Grimm**, JD Neaton, J Stamler, for the TOMHS Research Group. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). *Circulation* 1995; 91(3):698-706.
102. PJ Elmer, **R Grimm**, B Laing, G Grandits, K Svendsen, N Van Heel, E Betz, J Raines, M Link, J Stamler, J Neaton, for the TOMHS Research Group. Lifestyle intervention: Results of the Treatment of Mild Hypertension Study (TOMHS). *Prev Med* 1995;24:378-388.
103. M Alderman, **R Grimm**, JD Swales, CW Weart. Treating hypertension: Which drugs first? *Patient Care* 1995;29(16):72-99.
104. J Flack, J Neaton, **R Grimm**, J Shih, J Cutler, K Ensrud, S MacMahon. Blood pressure and mortality among men with prior myocardial infarction. *Circulation* 1995; 92(9):2437-45.
105. MA Pfeffer, FM Sacks, LA Moyé, L Brown, JL Rouleau, H Hartley, J Rouleau, **R Grimm**, F Sestier, W Wickemeyer, TG Cole, E Braunwald, for the CARE Investigators. Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients. *Am J Cardio* 1995;76:98C-106C.
106. S Wassertheil-Smoller, WB Applegate, K Berge, CJ Chang, BR Davis, **R Grimm**, J Kostis, S Pressel, E Schron, for the SHEP Cooperative Research Group. Change in depression as a precursor of cardiovascular events. *Arch of Intern Med* 1996; 156:553-61.
107. BR Davis, JA Cutler, DJ Gordon, CD Furberg, JT Wright, Jr, WC Cushman, **RH Grimm**, J LaRosa, PK Whelton, HM Perry, MH Alderman, CE Ford, S Oparil, C Francis, M Proschan, S Pressel, HR Black, CM Hawkins, for the ALLHAT Research

- Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Am J Hypertension* 1996; 9(4) Part I:342-60.
108. **RH Grimm**, JM Flack, GA Grandits, PJ Elmer, JD Neaton, JA Cutler, C Lewis, R McDonald, J Schoenberger, J Stamler, for the TOMHS Research Group. Long-term effects on plasma lipids of diet and drugs to treat hypertension. *JAMA* 1996; 275(20):1549-56.
 109. **RH Grimm**, JM Flack, JA Schoenberger, NM Gonzalez, PR Liebson. a-blockade and thiazide treatment of hypertension: A double-blind randomized trial comparing doxazosin and hydrochlorothiazide. *Am J Hypertension* 1996; 9(5):445-54.
 110. PR Liebson, G Grandits, **RH Grimm**. Regression of left ventricular hypertrophy. *JAMA* 1996; 276(7):826-7 (letter).
 111. **RH Grimm**, GA Grandits, RJ Prineas, RH McDonald, CE Lewis, JM Flack, C Yunis, K Svendsen, PR Liebson, PJ Elmer, J Stamler, for the TOMHS Research Group. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: The Treatment of Mild Hypertension Study. *Hypertension* 1997; 29(1 pt 1):8-14.
 112. **RH Grimm**, GA Grandits, JA Cutler, AL Stewart, RH McDonald, K Svendsen, RJ Prineas, PR Liebson, for the TOMHS Research Group. Relationships of quality of life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study (TOMHS). *Arch Int Med* 1997; 157:638-648.
 113. JB Kostis, BR Davis, J Cutler, **RH Grimm**, et al, for the SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. *JAMA* 1997; 278(3):212-216.
 114. MC Ganguli, **RH Grimm, Jr**, KH Svendsen, JM Flack, GA Grandits, PJ Elmer, for the TOMHS Research Group. Higher education and income is related to a better Na:K ratio in blacks: Baseline results of the Treatment of Mild Hypertension Study (TOMHS) data. *Am J Hypertension* 1997; 10:979-984.
 115. **RH Grimm Jr**, KH Svendsen, B Kasiske, WF Keane, MM Wahi, for the MRFIT Research Group. Proteinuria as a risk factor for mortality over 10 years of follow-up. *Kidney Intl* 1997; in press.
 116. **RH Grimm Jr**, Not Black and white. *Am J Hypertension* 1997;10:1426-1427.

117. **RH Grimm Jr**, Warning-the physician's clinical judgement can be hazardous to your health: withdrawing drugs in patients with high blood pressure. *J Am Board Fam Practice* 1997;10:305-307.
118. **RH Grimm Jr**, Intersalt data. Collaborative efforts must be made to reduce sodium in diet. *BMJ* 1997;315:487.
119. **RH Grimm Jr**, A Pemberton, Association versus causation: the relationship of interleukin-1 beta and hypertension. *J Lab Clin Medicine* 1997;129:283-284.
120. **RH Grimm Jr**, G Grandits, JM Flack, Are black and white hypertensives really different? *ABC Digest of Urban Cardiology* 1997:10-16.
121. **RH Grimm Jr**, GA Grandits, JA Cutler, et al, for the TOMHS Research Group. Quality-of-life measures improved in a mild hypertension study. *ACP Journal Club* September/October 1997:37.
122. **RH Grimm Jr**, G Grandits, JA Cutler et al., for the TOMHS Research Group. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. *Arch Intern Med*;1997 Mar 24;157:638-48.
123. **RH Grimm Jr**, KH Svendsen, B Kasiske, WF Keane, MM Wahi. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. *Kidney International - Suppl*;1997 December;63:S10-14.
124. PR Liebson, RJ Prineas, **RH Grimm Jr**. Regression of left ventricular mass in the treatment of hypertension: successes and caveats. *Preventive Cardiology* Spring 1998;24-32.
125. HR Black, WJ Elliot, JD Neaton, G Grandits, P Gramsbsh, **RH Grimm Jr**, L Hansson, Y Lacouciere, J Muller, P Sleight, MA Weber, WB White, G Williams, J Wittes, A Zanchetti, TD Fakouhi for the CONVINCE Research Group. Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. *Controlled Clinical Trials* 1998;19:370-390.
126. **RH Grimm Jr** et al. Related guidelines and reviews - update on hypertension, long-term effects on plasma lipids of diet and drugs to treat hypertension. *Abstracts of Clinical Care Guidelines* 1998;10(3):19.
127. HR Black, WJ Elliott, JD Neaton, GA Grandits, P Grambsch, **RH Grimm Jr**, L Hansson, Y Lacouciere, J Muller, P Sleight. MA Weber, WB White, J

treatment in post-menopausal women: baseline data from the women's health initiative. *Hypertension* 2000;36:780-789

138. HR Black, WJ Elliott, JD Neaton, G Grandits, P Grambsch, **RH Grimm Jr**, L Hansson, Y Lacouciere, J Muller, P Sleight, MA Weber, WB White, G Williams, J Wittes, A Zanchetti, TD Fakouhi, RJ Anders. Baseline characteristics and early blood pressure control in the CONVINCE trial. *Hypertension (Online)*:2001 January;37(1):12-18.
139. **RH Grimm Jr**, KL Margois, V Papademetriou, WC Cushman, CE Ford, J Bettencourt, MH Alderman, JN Basile, HR Black, V DeQuattro, J Eckfeldt, CM Hawkins, HM Perry, M Proschan. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension (Online)*:2001 January;37(1):19-27.
140. GA Grandits, **RH Grimm Jr**, RJ Prineas, P Grambsch, LA Holland. Obtaining event status at the close of the Treatment of Mild Hypertension Study: methods and implication for other trials. *Control Clin Trials*;2001 February;22(1):56-61.
141. HR Black, WJ Elliott, JD Neaton, G Grandits, P Grambsch, **RH Grimm**, L Hansson, Y Lacouciere, J Muller, P Sleight, MA Weber, WB White, G Williams, J Wittes, A Zanchetti, TD Fakouhi, RJ Anders, for the CONVINCE Research Group. Baseline characteristics and early blood pressure control in the CONVINCE trial. *Hypertension* 2001;37:12-18
142. JP Roel, **RH Grimm**. Hypertension and erectile dysfunction: a review. *Med Aspects Human Sex* 2001;1(3):33-39.
143. GA Grandits, **RH Grimm**, RJ Prineas, LA Holland. Obtaining event status at the close of the treatment of mild hypertension study: methods and implication for other trials. *Controlled Clinical Trials* 2001;22:56-61
144. **RH Grimm** , KL Margolis, V Papademetriou, W Cushman, C. Ford, J Bettencourt, M Alderman, J Basile, H Black, V DeQuattro, J Eckfeldt, M Hawkins, M Perry, M Proschan. Baseline characteristics of the participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). *Hypertension* 2001;37:19-27.
145. JP Roel, CL Hildebrandt, **RH Grimm Jr**. Quality of life with nonpharmacologic treatment of hypertension. *Current Hypertension Reports*:2001 December;3(6):466-472.

146. **RH Grimm Jr**, H Black, R Rowen, A Lewin, H Shi, M Ghadanfar, Amlodipine Study Group. Amlodipine versus chlorthalidone versus placebo in the treatment of stage 1 isolated systolic hypertension. *Am J Hypertension*:2002 January;15(1 Pt 1):31-36.
147. **RH Grimm Jr**. Commentary, ACP Journal Club (March/April 2002), p. 46.
148. M Domanski, G Mitchell, M Pfeffer, J Neaton, J Norman, K Svendsen, **RH Grimm**, J Cohen, J Stamler, for the MRFIT Research Group. Pulse pressure and cardiovascular disease-related mortality. *JAMA*:2002;287(20):2677-2683.
149. SJ Rolnick, KL Margolis, KK Fortman, MV Maciosek, **RH Grimm**. How acceptable are financial incentives and written feedback for improving hypertension control? Perspectives from physicians, clinic administrators, and patients. *Am J Manag Care*:2002 May;8(5):441-447.
150. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. *JAMA*:2002 July;288(3):321-333.
151. CH Goertz, **RH Grimm**, K Svendsen, G Grandits. Treatment of Hypertension with Alternative Therapies (THAT) Study: A randomized clinical trial. *J Hypertens* 2002;20(10):2063-2068.
152. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papdemetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hypertension* 2002;4:393-404
153. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*:2002 December 18;288(23):2981-2997.
154. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. *JAMA*:2002 December 18;288(23):2998-3007.